
by OMNI ADRD
There might not be a cure for Alzheimer’s disease, but we may be able to prevent it.
The primary biological drivers of Alzheimer’s disease are the buildup of amyloid-beta plaques and tau tangles in the brain. Current treatments for Alzheimer’s disease and related dementias (AD/ADRD) include drugs that affect levels of neurotransmitters to temporarily boost cognition, and newer drugs that target amyloid-beta. These newer drugs can slow cognitive decline, especially when given shortly after diagnosis, but they’re not a cure. They cannot reverse existing neurological damage.
New and better treatments are on the horizon, including several promising therapies that aim to reduce tau buildup in the brain. But even these treatments are not expected to reverse existing damage or improve cognition. That’s why so many AD/ADRD researchers are focusing on prevention: stopping the onset of disease before significant neurological damage occurs.
A Lengthy Disease Process
In Alzheimer’s disease, abnormal protein buildup damages brain cells over time. Amyloid plaques are clumps of amyloid-beta protein fragments that cluster around brain cells. Tau tangles are long fibers of tau that become abnormally twisted inside brain cells. As these proteins accumulate in and around neurons, they impair the cells’ ability to communicate and eventually cause them to die.
Studies of protein levels in the brain and in the cerebrospinal fluid (the fluid surrounding the brain and spinal cord) show that this buildup starts at least 10 to 20 years before cognitive impairment. After years of accumulation, specific brain areas begin to shrink, including the hippocampus—a region critical for learning and memory. These changes in brain volume also precede cognitive impairment by years.
Preventing AD/ADRD by Intervening in Midlife
We still don’t know the optimal time to intervene. Is it before loss of brain volume? Before amyloid-beta or tau buildup begins? Before that buildup reaches a tipping point, after which further accumulation and cognitive decline become inevitable?
What we do know is that prevention needs to happen well before a diagnosis—that is, it needs to happen in midlife.
The good news is that many behaviors that boost health in midlife are also linked with a reduced risk of Alzheimer’s disease. The 2024 report of the Lancet Commission on dementia prevention, intervention, and care found that up to 45% of dementia cases might be preventable by addressing 14 modifiable risk factor interventions:
- Being mentally active and engaging in cognitively stimulating activities
- Treating hearing loss and decreasing harmful noise exposure to prevent hearing loss
- Treating depression
- Using helmets and head protection in contact sports and on bicycles
- Being physically active
- Not smoking
- Preventing and treating high blood pressure
- Treating high LDL cholesterol from midlife on
- Maintaining a healthy weight and treating obesity as early as possible
- Preventing and managing diabetes
- Avoiding high levels of alcohol intake
- Being socially active
- Treating vision loss
- Reducing exposure to air pollution
Bridging Gaps in Early Intervention Research
There’s a lot we can already do that is likely to lower our risk for dementia. However, we still don’t know enough about many of these risk factors to understand how they prevent dementia or to give specific recommendations to people hoping to lower their risk.
Take exercise as an example. It may lower dementia risk directly, by enhancing blood flow to the brain and production of neuroprotective chemicals. It may also work indirectly, by improving immune function and cardiovascular health and reducing inflammation. But we don’t know how much exercise people need, what types of exercise are best, or how long they must keep it up to meaningfully reduce their risk. We also don’t know whether exercise prevents amyloid or tau buildup, slows it, or simply enhances cognition enough that people can continue to function despite this accumulation.
We need intervention studies that address these types of questions to determine which lifestyle, social, and environmental changes meaningfully reduce dementia risk and when they are needed. In other words, we need to know what to do, for whom, and when. We also need to know which interventions help people make meaningful, sustainable changes.
And because we don’t want to wait decades to find out, we need ways to assess the subtle changes that occur before cognitive impairment—both in cognition and in biomarkers like amyloid-beta buildup—to determine whether the interventions we try are working.
Where OMNI ADRD Comes In
OMNI ADRD aims to power AD/ADRD prevention studies by helping researchers identify early signs of increased dementia risk. We’re surveying and documenting the currently available measures that can detect subtle cognitive changes, so researchers can choose the right tools to determine whether their interventions are working and, ultimately, learn what to do, for whom, and when.



